AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33766254 — intervention group
Group type: EXPERIMENTAL
Intervention: Siemens Diagnostics hs-cTn assay
Number of subjects: 624
Study 33766254 — intervention group
Group type: EXPERIMENTAL
Intervention: Management recommendations based on hs-cTn measurements
Number of subjects: 624
Study 33766254 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge recommendations
Number of subjects: 624
Study 33766266 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation
Number of subjects: 0
Study 33766266 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 33766502 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive image-guided standard radiotherapy
Number of subjects: 0
Study 33766502 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-escalated tumour boost radiotherapy
Number of subjects: 0
Study 33766502 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33766817 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus CAPOX
Number of subjects: 48
Study 33766817 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus CAPOX followed by camrelizumab plus apatinib
Number of subjects: 48
Study 33766834 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS)
Number of subjects: 30
Study 33766844 — intervention group
Group type: EXPERIMENTAL
Intervention: Community delivery of intermittent preventive treatment (C-IPTp) with sulfadoxine-pyrimethamine at each scheduled antenatal care (ANC) visit.
Number of subjects: 0
Study 33766994 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric and cognitive symptoms in HD gene carriers
Number of subjects: 6316
Study 33766994 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmotor symptoms
Number of subjects: 6316
Study 33767059 — intervention group
Group type: EXPERIMENTAL
Intervention: APOL1 gene expression induction
Number of subjects: 0
Study 33767059 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel therapeutic development inhibiting APOL1 synthesis or function
Number of subjects: 0
Study 33767059 — intervention group
Group type: EXPERIMENTAL
Intervention: APOL1 variants
Number of subjects: 0
Study 33767061 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of kidney replacement therapy (KRT)
Number of subjects: 4
Study 33767061 — intervention group
Group type: COMPARATOR
Intervention: Delayed initiation of kidney replacement therapy (KRT)
Number of subjects: 4
Study 33767093 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0
Study 33767093 — intervention group
Group type: EXPERIMENTAL
Intervention: C5 inhibitors and daptomycin
Number of subjects: 0
Study 33767093 — intervention group
Group type: EXPERIMENTAL
Intervention: Early antibiotics
Number of subjects: 0
Study 33767093 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF culture and PCR
Number of subjects: 0
Study 33767093 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct next-generation sequencing of CSF
Number of subjects: 0
Study 33767162 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose tamoxifen (5 mg/day)
Number of subjects: 0
Study 33767648 — intervention group
Group type: EXPERIMENTAL
Intervention: iACTwithPain intervention (eight weekly self-management sessions)
Number of subjects: 0
Study 33767648 — intervention group
Group type: COMPARATOR
Intervention: ACT-only intervention
Number of subjects: 0
Study 33767648 — intervention group
Group type: COMPARATOR
Intervention: Medical TAU group
Number of subjects: 0
Study 33767695 — intervention group
Group type: EXPERIMENTAL
Intervention: BCMA-7 × 19 CAR-T cells
Number of subjects: 2
Study 33767713 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Interferon-α Levels
Number of subjects: 0
Study 33768217 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased uromodulin expression in overweight patients
Number of subjects: 0
Study 33768217 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased uromodulin expression in older patients
Number of subjects: 0
Study 33768217 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased uromodulin expression in patients with hypertension
Number of subjects: 0
Study 33768227 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap vaccination (Boostrix, GSK Biologicals) during pregnancy
Number of subjects: 234
Study 33768227 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (unvaccinated control group)
Number of subjects: 234
Study 33768419 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab 350 mg Q3W
Number of subjects: 505
Study 33768419 — intervention group
Group type: COMPARATOR
Intervention: Cemiplimab 3 mg/kg Q2W
Number of subjects: 505
Study 33768426 — intervention group
Group type: EXPERIMENTAL
Intervention: PD with external biliary stent (PD-BS)
Number of subjects: 128
Study 33768426 — intervention group
Group type: COMPARATOR
Intervention: Standard PD (ST-PD)
Number of subjects: 128
Study 33768488 — intervention group
Group type: EXPERIMENTAL
Intervention: Teprotumumab (10 mg/kg initial intravenous infusion followed by 20 mg/kg every 3 weeks for 7 additional infusions)
Number of subjects: 0
Study 33768488 — intervention group
Group type: EXPERIMENTAL
Intervention: Teprotumumab
Number of subjects: 0
Study 33768637 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic and arachidonic acid supplementation at 1 year
Number of subjects: 0
Study 33768637 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33768961 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Education (PE) lessons
Number of subjects: 10697
Study 33768961 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitness-focused lessons
Number of subjects: 10697
Study 33768961 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls-only lessons
Number of subjects: 10697
Study 33768961 — intervention group
Group type: EXPERIMENTAL
Intervention: Field athletics
Number of subjects: 10697
Study 33768961 — intervention group
Group type: EXPERIMENTAL
Intervention: Enjoyment of PE
Number of subjects: 10697
Study 33769076 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib + lenalidomide + dexamethasone
Number of subjects: 0
Study 33769076 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33769295 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic virtual reality human-human interface
Number of subjects: 109
Study 33769300 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet intervention for 12 weeks
Number of subjects: 12
Study 33769300 — intervention group
Group type: EXPERIMENTAL
Intervention: Development and validation of a diabetes-specific quality of life questionnaire
Number of subjects: 12
Study 33769355 — intervention group
Group type: EXPERIMENTAL
Intervention: Saroglitazar 4 mg daily for 16 weeks
Number of subjects: 7
Study 33769417 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon (Xe) inhalation for 24 hours after resuscitation
Number of subjects: 0
Study 33769417 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide (NO), molecular hydrogen (H2), xenon (Xe), and argon (Ar)
Number of subjects: 0
Study 33769417 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon (Xe) combined with targeted temperature management
Number of subjects: 0
Study 33769417 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon (Xe) and hydrogen (H2)
Number of subjects: 0
Study 33769417 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled gases (Xe, Ar, NO, H2)
Number of subjects: 0
Study 33769497 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib, an anti-angiogenic tyrosine kinase inhibitor, administered once daily until disease progression, unmanageable toxicity, withdrawal, or death.
Number of subjects: 20
Study 33769555 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based interventions (including SMS, healthcare worker training, face-to-face counselling, electronic pillboxes, written materials, home blood pressure monitors)
Number of subjects: 25633
Study 33769555 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based interventions
Number of subjects: 25633
Study 33769555 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based interventions (SMS and provider support)
Number of subjects: 25633
Study 33769555 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based interventions (SMS only)
Number of subjects: 25633
Study 33769589 — intervention group
Group type: EXPERIMENTAL
Intervention: Clean intermittent self-catheterization (CISC)
Number of subjects: 25
Study 33769768 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency department-based HIV screening strategies
Number of subjects: 0
Study 33769768 — intervention group
Group type: COMPARATOR
Intervention: Current screening strategies
Number of subjects: 0
Study 33769953 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with adrenal crises (AC)
Number of subjects: 2694
Study 33769953 — intervention group
Group type: EXPERIMENTAL
Intervention: PAI patients with AC
Number of subjects: 2694
Study 33769953 — intervention group
Group type: EXPERIMENTAL
Intervention: SAI patients with AC
Number of subjects: 2694
Study 33770018 — intervention group
Group type: EXPERIMENTAL
Intervention: IOLMaster 700 (biometer A)
Number of subjects: 50
Study 33770018 — intervention group
Group type: EXPERIMENTAL
Intervention: ANTERION (biometer B)
Number of subjects: 50
Study 33770018 — intervention group
Group type: EXPERIMENTAL
Intervention: LENSTAR, LS900 (biometer C)
Number of subjects: 50
Study 33770291 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 3
Study 33770527 — intervention group
Group type: EXPERIMENTAL
Intervention: Scale for the Assessment and Rating of Ataxia (SARA)
Number of subjects: 602
Study 33770527 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities of Daily Living (ADL)
Number of subjects: 602
Study 33770575 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib (125 mg orally on days 1-21 of a 28-day cycle)
Number of subjects: 15
Study 33770779 — intervention group
Group type: EXPERIMENTAL
Intervention: Riemannian spatial pattern method
Number of subjects: 0
Study 33770805 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA injection (100 units)
Number of subjects: 237
Study 33771219 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of poorer-quality food items during main meals
Number of subjects: 149
Study 33771219 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiota analysis
Number of subjects: 149
Study 33771219 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaled gas levels and symptom severity prediction
Number of subjects: 149
Study 33771219 — intervention group
Group type: EXPERIMENTAL
Intervention: Covariations between gut microbiota and diet
Number of subjects: 149
Study 33771233 — intervention group
Group type: EXPERIMENTAL
Intervention: HENRY intervention (Health, Exercise and Nutrition for the Really Young)
Number of subjects: 51
Study 33771233 — intervention group
Group type: COMPARATOR
Intervention: Cluster randomisation
Number of subjects: 51
Study 33771233 — intervention group
Group type: COMPARATOR
Intervention: Recommendations for public health intervention trials
Number of subjects: 51
Study 33771287 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 283
Study 33771287 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 283
Study 33771287 — intervention group
Group type: COMPARATOR
Intervention: Non-opioid detoxification
Number of subjects: 283
Study 33771694 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadal development and maturation (activation of the HPG-axis)
Number of subjects: 0
Study 33771694 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal repeated-measures sampling
Number of subjects: 0
Study 33771694 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine measures collection
Number of subjects: 0
Study 33771694 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI activation and resting-state networks
Number of subjects: 0
Study 33771703 — intervention group
Group type: EXPERIMENTAL
Intervention: DE-Un
Number of subjects: 75
Study 33771703 — intervention group
Group type: EXPERIMENTAL
Intervention: DE-Mth
Number of subjects: 75
Study 33771703 — intervention group
Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 75
Study 33771853 — intervention group
Group type: EXPERIMENTAL
Intervention: Evofosfamide (400-640 mg/m2) in combination with Ipilimumab
Number of subjects: 22
Study 33771885 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide/abiraterone
Number of subjects: 48
Study 33772397 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral neuromuscular stimulation device (NMES), used for 20 min once daily for a 6-week period.
Number of subjects: 70
Study 33772428 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic treatment (including Factor Xa inhibitors/direct thrombin inhibitors and antiplatelet therapy)
Number of subjects: 1660
Study 33772428 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor Xa inhibitors/direct thrombin inhibitors
Number of subjects: 1660
Study 33772428 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor Xa/DTI + APs
Number of subjects: 1660
Study 33772591 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia patients
Number of subjects: 20
Study 33772591 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 20
Study 33772822 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld smartphone ECG (iECG)
Number of subjects: 115
Study 33773011 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33773200 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported sleep efficiency on heavier-drinking days
Number of subjects: 56
Study 33773200 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported alcohol use following days of better sleep efficiency
Number of subjects: 56
Study 33773200 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective sleep efficiency
Number of subjects: 56
Study 33773200 — intervention group
Group type: COMPARATOR
Intervention: Objective measures of sleep efficiency
Number of subjects: 56
Study 33773443 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33773598 — intervention group
Group type: COMPARATOR
Intervention: Aβ-negative subjects
Number of subjects: 686
Study 33773598 — intervention group
Group type: COMPARATOR
Intervention: Subjects in the 'gray zone'
Number of subjects: 686
Study 33773598 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with established Aβ pathology (MCI)
Number of subjects: 686
Study 33773598 — intervention group
Group type: COMPARATOR
Intervention: Aβ-negative subjects and gray zone subjects
Number of subjects: 686
Study 33773598 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutoffs for amyloid PET abnormality
Number of subjects: 686
Study 33774438 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative BDNF serum levels
Number of subjects: 45
Study 33774438 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative BDNF serum levels (T2)
Number of subjects: 45
Study 33774438 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative BDNF serum levels (T4)
Number of subjects: 45
Study 33774669 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX optimization (72% of patients)
Number of subjects: 722
Study 33774669 — intervention group
Group type: EXPERIMENTAL
Intervention: bDMARD initiation ± MTX (16% of patients)
Number of subjects: 722
Study 33774745 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab and mycophenolate mofetil (MMF)
Number of subjects: 2
Study 33774767 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS0728 at 200 mg BID
Number of subjects: 19
Study 33774767 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS0728 at 150 mg BID
Number of subjects: 19
Study 33774767 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS0728 treatment response
Number of subjects: 19
Study 33774800 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 100
Study 33774800 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial changes in interelectrode conduction times
Number of subjects: 100
Study 33775123 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular endothelial growth factor receptor inhibition
Number of subjects: 0
Study 33775123 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33775127 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 0
Study 33775127 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure control
Number of subjects: 0
Study 33775523 — intervention group
Group type: EXPERIMENTAL
Intervention: Galsulfase enzyme replacement therapy (ERT)
Number of subjects: 3
Study 33776633 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment group (6 months treatment)
Number of subjects: 144
Study 33776633 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 144
Study 33776798 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual exercise program from 8-10 to 38-39 weeks of pregnancy
Number of subjects: 72
Study 33776798 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 72
Study 33776891 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33776910 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 306
Study 33776910 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic patients
Number of subjects: 306
Study 33776910 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic non-survivors
Number of subjects: 306
Study 33776910 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic survivors
Number of subjects: 306
Study 33776910 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-survival diabetic cases
Number of subjects: 306
Study 33776922 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM group
Number of subjects: 162
Study 33776922 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 162
Study 33776937 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower plasma albumin concentration
Number of subjects: 0
Study 33777758 — intervention group
Group type: EXPERIMENTAL
Intervention: 38.5 Gy IMRT or 3D-CRT APBI w/3.85 Gy fraction/BID fractionation for 10 fractions
Number of subjects: 269
Study 33777758 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple negative and ER- statuses
Number of subjects: 269
Study 33777758 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple negative type
Number of subjects: 269
Study 33777758 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival for all patients
Number of subjects: 269
Study 33778020 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithmic interpretation of FFR pullback curves
Number of subjects: 0
Study 33778020 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33778051 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 analysis from pleural effusion
Number of subjects: 0
Study 33778174 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative ultrasound (QUS) during radical radiotherapy (RT) (70 Gy/33 fractions)
Number of subjects: 51
Study 33778174 — intervention group
Group type: EXPERIMENTAL
Intervention: QUS Delta-radiomics
Number of subjects: 51
Study 33778551 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic strain measurement at the distal descending aorta (DDA)
Number of subjects: 45
Study 33778551 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic strain measurement at the ascending aorta (AA)
Number of subjects: 45
Study 33778551 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse wave velocity (PWV) measurement
Number of subjects: 45
Study 33778621 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI examinations
Number of subjects: 532
Study 33778911 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcopenia-related factors (lower body function, handgrip strength, gait speed, appendicular skeletal muscle mass index-ASMI)
Number of subjects: 115
Study 33778911 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body function
Number of subjects: 115
Study 33778911 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical fitness (upper-and-lower-body strength, agility/dynamic balance, cardiorespiratory fitness, body mass index)
Number of subjects: 115
Study 33778911 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual physical activity
Number of subjects: 115
Study 33778911 — intervention group
Group type: EXPERIMENTAL
Intervention: Independence in activities of daily living (ADL)
Number of subjects: 115
Study 33778928 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrolizumab autoinjector (AI) 105 mg
Number of subjects: 30
Study 33778934 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Number of subjects: 45
Study 33778934 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (normal renal function)
Number of subjects: 45
Study 33779291 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol-paclitaxel-coated peripheral balloon catheter
Number of subjects: 784
Study 33779541 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep fragmentation (SF) as measured by sleep fragmentation index (SFI), arousal index (ArI), sleep efficiency (SE), and wake after sleep onset (WASO)
Number of subjects: 4887
Study 33779541 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep efficiency (SE)
Number of subjects: 4887
Study 33779567 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Engagement and Activation Platform (DEAP) - automated patient education tool; all 189 intervention patients accessed the first module, and 140 patients (74.1%) accessed all 9 modules.
Number of subjects: 337
Study 33779567 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (DEAP)
Number of subjects: 337
Study 33779567 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 337
Study 33779569 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth Transition Assistance Program (TAP) for caregivers of individuals with acute SCI
Number of subjects: 0
Study 33779569 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care control
Number of subjects: 0
Study 33779799 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT imaging and clinical factors
Number of subjects: 66